Roche's Genentech Inc. announced US Food and Drug Administration approval on 15 August for Rozlytrek (entrectinib) in two indications, making it the second drug approved in the US for solid tumors with a neurotrophic tyrosine receptor kinase (NTRK) gene fusion regardless of tumor type, behind Bayer AG's Vitrakvi (larotrectinib), which was cleared by the FDA last year.
Rozlytrek gained full approval to treat adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC) as well as accelerated approval...